Avanos Medical, Inc. Stockholders Approve Acquisition by American Industrial Partners

Rhea-AI Summary

Avanos Medical (NYSE: AVNS) announced that stockholders approved the pending acquisition of Avanos by affiliates of funds advised by American Industrial Partners (AIP) at a July 22, 2026 special meeting. Based on preliminary results, approximately 99.75% of shares voted supported the deal, representing about 74.96% of total outstanding common shares as of the June 18, 2026 record date.

Under the merger agreement, Avanos stockholders will have the right to receive $25.00 in cash per share at the effective time of the acquisition. Avanos stated that all required regulatory approvals under the merger agreement have been received and that the transaction is expected to close no later than July 27, 2026, subject to customary closing conditions. Final voting results will be detailed in a Form 8-K filing with the U.S. Securities and Exchange Commission.

Positive

• Cash consideration of $25.00 per Avanos (AVNS) share
• Deal support from 99.75% of shares voted at the special meeting
• Supporting votes represented 74.96% of total outstanding common shares
• All required regulatory approvals under the merger agreement have been received
• Transaction expected to close by July 27, 2026, subject to customary conditions

Negative

• None.

Market Context

Tag-specific acquisition events averaged a 17.7% 24-hour move across four events. The approval adds ...

Analysis

Tag-specific acquisition events averaged a 17.7% 24-hour move across four events. The approval adds a completed milestone, while customary closing conditions remained relevant and low short positioning supplied additional context.

Key Figures

Approval vote: 99.75% of shares voted Outstanding shares represented: 74.96% Cash consideration: $25.00 per share +3 more

6 metrics

Approval vote 99.75% of shares voted Shares voted in favor of the acquisition

Outstanding shares represented 74.96% Total outstanding shares as of the June 18, 2026 record date

Cash consideration $25.00 per share Amount payable at the effective time of the acquisition

Expected closing date July 27, 2026 Transaction expected to close no later than this date

Special meeting date July 22, 2026 Date of the stockholder vote

Record date June 18, 2026 Date used to determine eligible shares for the Special Meeting

Previous Acquisition Reports

4 past events · Latest: Jul 02 (Positive)

Same Type Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 02	Regulatory approval	Positive	+1.2%	All required regulatory approvals received for the pending AIP merger.
Apr 14	Acquisition agreement	Positive	+69.5%	AIP agreed to acquire Avanos for $25.00 cash per share.
Oct 23	Business asset sale	Neutral	-0.3%	WRS Group agreed to acquire Avanos's U.S. Game Ready rental business.
Sep 15	Company acquisition	Positive	+0.4%	Avanos acquired Nexus Medical to expand critical-care nutrition technology.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Three acquisition-tag events had positive 24-hour reactions, while the October 23 asset-sale announcement had a -0.34% reaction.

Key Terms

merger agreement, effective time, customary closing conditions, form 8-k

4 terms

merger agreement regulatory

"pursuant to the terms of the merger agreement"

A merger agreement is a binding contract that lays out the exact terms for two companies to combine, including the price, what each side will deliver, and the conditions that must be met before the deal is completed. Investors care because it sets the timetable, payouts and risks — like a blueprint or prenup that shows whether the deal is likely to close, how ownership will change, and what could cancel or alter the payout they expect.

effective time regulatory

"at the effective time of the acquisition"

The exact clock time when a regulatory filing, approval, or corporate action formally becomes legally active; from that moment the change is binding and can be acted on. Investors care because the effective time marks when ownership, rights, trading rules, or new securities take effect — like a light switch turning on a contract or transaction — which determines when risks, benefits and market reactions begin.

customary closing conditions regulatory

"subject to the satisfaction or waiver of customary closing conditions"

"Customary closing conditions" are standard rules or checks that must be met before a business deal can be finalized, like making sure all paperwork is in order or that certain approvals are obtained. They matter because they help protect both parties, ensuring everything is in place and reducing the risk of surprises or problems after the deal is closed.

form 8-k regulatory

"Current Report on Form 8-K to be filed by the Company"

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ALPHARETTA, Ga., July 22, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) ("Avanos" or the "Company"), a leading medical technology company, today announced that its stockholders have voted to approve the pending acquisition of Avanos by affiliates of investment funds advised by American Industrial Partners ("AIP") at a special meeting of stockholders (the "Special Meeting") held earlier today.

Based on preliminary voting results, approximately 99.75% of shares voted at the Special Meeting were voted in favor of the transaction, which represented approximately 74.96% of the total outstanding shares of Avanos common stock as of June 18, 2026, the record date for the Special Meeting.

"We are pleased with the outcome of the Special Meeting and thank our stockholders for their strong support," said Gary D. Blackford, Avanos' Board chair. "By partnering with AIP, we expect to build on our positive momentum with enhanced flexibility and resources, enabling Avanos to better address today's most pressing healthcare needs. We look forward to closing the transaction as Avanos enters the next chapter in its history."

As previously announced, pursuant to the terms of the merger agreement, Avanos stockholders will have the right to receive $25.00 per share in cash at the effective time of the acquisition for each share of Avanos common stock they own. All required regulatory approvals under the merger agreement have been received. The transaction is expected to close no later than July 27, 2026, subject to the satisfaction or waiver of customary closing conditions.

The final voting results of the Special Meeting will be set forth in a Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission.

About Avanos Medical, Inc.

Avanos Medical, Inc. is a medical technology company focused on delivering clinically superior medical device solutions that will help patients get back to what matters. Headquartered in Alpharetta, Georgia, we are committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands globally and holds leading market positions in multiple categories across its portfolio. For more information, visit avanos.com and follow Avanos Medical on X (@AvanosMedical), LinkedIn and Facebook.

Forward-Looking Statements

This press release contains information that includes or is based on "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as "expect," "may," or "will," and similar expressions. These forward-looking statements include statements about the expected timing of the closing of the merger and other matters. These statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including the risk that the merger may not be completed on the anticipated timeline or at all. Avanos undertakes no obligation to update or revise any forward-looking statements.

Contacts

Investor Relations Contact:

Scott Galovan, Avanos Medical, Inc., Investor.Relations@Avanos.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/avanos-medical-inc-stockholders-approve-acquisition-by-american-industrial-partners-302832518.html

SOURCE Avanos Medical

FAQ

What did Avanos Medical (NYSE: AVNS) stockholders approve on July 22, 2026?

Avanos Medical stockholders approved the pending acquisition of Avanos by affiliates of funds advised by American Industrial Partners. According to Avanos, this approval followed a special meeting where the vast majority of votes cast supported the transaction, enabling the deal to move toward closing.

How much will Avanos Medical (AVNS) shareholders receive per share in the AIP acquisition?

Avanos Medical shareholders will have the right to receive $25.00 in cash per AVNS share at closing. According to Avanos, this consideration applies for each share of Avanos common stock owned at the effective time of the acquisition, under the existing merger agreement.

What percentage of Avanos Medical (AVNS) shares voted in favor of the AIP acquisition?

Approximately 99.75% of Avanos shares voted at the special meeting supported the acquisition. According to Avanos, these votes represented about 74.96% of the total outstanding common shares as of the June 18, 2026 record date, indicating broad stockholder support.

When is the Avanos Medical (NYSE: AVNS) acquisition by American Industrial Partners expected to close?

The Avanos acquisition by American Industrial Partners is expected to close no later than July 27, 2026. According to Avanos, all required regulatory approvals have been received, and completion now depends on the satisfaction or waiver of remaining customary closing conditions in the merger agreement.

Have all regulatory approvals for the Avanos Medical (AVNS) and American Industrial Partners deal been obtained?

Yes, all required regulatory approvals under the merger agreement have been received for the Avanos and AIP transaction. According to Avanos, with regulatory clearances complete, the acquisition mainly awaits satisfaction or waiver of customary closing conditions before it can become effective.

Where will final voting results for the Avanos Medical (NYSE: AVNS) special meeting be reported?

Final voting results from the Avanos special meeting will be reported in a Form 8-K. According to Avanos, this Current Report on Form 8-K will be filed with the U.S. Securities and Exchange Commission, providing detailed certified vote tallies for the acquisition approval.